27
Feb

Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer’s disease, adding measures of brain function to an ongoing trial.

…read more

Source: Novartis looks to squelch neuro worries over its would-be cardio blockbuster

    

0 No comments